SYS-CON MEDIA Authors: Unitiv Blog, Kevin Benedict, Mark R. Hinkle, Glenn Rossman, Jason Bloomberg

News Feed Item

Autonomic Technologies Appoints Shashidhar Kori, M.D. As New Chief Medical Officer

REDWOOD CITY, California, January 21, 2014 /PRNewswire/ --

Autonomic Technologies, Inc. (ATI) announces the appointment of Dr. Shashidhar Kori, M.D. to the position of Chief Medical Officer.

Dr. Kori has more than 30 years experience in the field of neurosciences. Most recently, Dr. Kori was Vice President of Clinical Development and Medical Affairs at Allergan and MAP Pharmaceuticals.  Previously he was Senior Director of Clinical Development and Senior Medical Advisor on the Pain/Migraine Team at GlaxoSmithKline. In these leadership roles, Dr. Kori led the design and execution of numerous clinical studies to support product development and commercialization, built and oversaw an active publication strategy, created a new medical affairs department, served as liaison to the external scientific and medical community, and had significant involvement in new product development and discussions with global regulatory authorities.

In his new role, Dr. Kori is responsible for clinical research, clinical outcomes, and regulatory submissions.  He will oversee development and execution of all clinical research, including clinical trials of the ATI™ Neurostimulation System for cluster headache and migraine in Europe and the United States.  He will also lead interactions with regulatory authorities.

"Dr. Kori brings a wealth of experience to ATI from many years of work at leading pharmaceutical companies in the headache space and also as a physician," said Ben Pless, President and Chief Executive Officer of ATI.  "Shashi is widely recognized and well respected in the field of neurology and neuroscience, and headache in particular. We are pleased and fortunate to have such a capable and accomplished leader join ATI at this important point in our company's growth."

In addition to his industry experience, Dr. Kori has a distinguished academic career.  He founded, built, and ran four large pain programs, including the Pain and Palliative Care Program at Duke University where he was the Founding Director.  He founded and managed large clinical and residency programs, and he held leadership, teaching, and administrative posts at Duke University, the University of South Florida College of Medicine, and Case Western Reserve University. Dr. Kori has held positions in professional organizations including the American Academy of Neurology, Southern Pain Society, American Society for Neuroimaging, and the South Eastern Academic Pain Consortium. He has authored more than 90 publications, served on editorial boards of medical journals, and has given more than 150 U.S. and international invited lectures on pain and headache management.

Dr. Kori received his medical degree from Kasturba Medical College in Mangalore, India. He completed residencies in Internal Medicine at the VA Medical Center in Brooklyn, NY, and Neurology at St. Vincent's Hospital and Medical Center in New York, NY. He served fellowships in Neuro-oncology, Neuroimmunology and Immunobiology, and Cancer Pain at Memorial Sloan-Kettering Cancer Center, NY.

About Autonomic Technologies

Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company's initial product, the ATI Neurostimulation System, is CE marked in Europe for the treatment of cluster headache and is currently being investigated in a multi-center, randomized study for the treatment of high frequency, high disability migraine.

The ATI Neurostimulation System was voted #2 among the Cleveland Clinic's top 10 medical innovations for 2013 and was chosen to receive a 2013 Best of What's New Award from Popular Science in the Health category.  ATI was named one of FierceMedicalDevices' 2012 Fierce 15 most promising privately held medical device and diagnostics companies in the world.

ATI is headquartered in the San Francisco Bay Area and is backed by blue chip investors Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic.  For more information, visit http://www.ati-spg.com.

Contact:
Brit Gould
Autonomic Technologies, Inc.
+1-650-395-4230
[email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.